Stallergenes Greer Appoints CEOLIA as New Promotional Partner for Actair® in Japan, Concluding 13-Year Collaboration with Shionogi
Stallergenes Greer, a global leader in allergen immunotherapy, has announced a strategic transition in the Japanese market for its flagship product, Actair®, a sublingual immunotherapy (SLIT) tablet used for the treatment of allergic rhinitis caused by house dust mites. As of July 3, 2025, the promotional responsibilities for Actair® in Japan will shift from Shionogi & Co., Ltd. to CEOLIA Pharma Co. Ltd, marking a significant shift in the company’s commercial strategy in the region.
This transition follows the termination of a licensing agreement that had been in place since 2010, under which Shionogi had been responsible for the development, regulatory registration, and commercialization of Actair® within the Japanese market. The long-standing partnership has played a vital role in establishing and expanding access to allergen immunotherapy in Japan, particularly for patients suffering from respiratory allergies linked to house dust mites.
Despite the end of the formal license agreement, Shionogi will remain actively involved during a transition period. The company will continue to serve as the Marketing Authorization Holder (MAH) in Japan and maintain responsibility for the importation, manufacturing, and distribution of Actair®. Additionally, Shionogi will provide operational and knowledge transfer support to CEOLIA to ensure a seamless transition, avoiding any disruption in patient care or healthcare professional engagement.
This collaborative handover is structured to preserve treatment continuity for patients and ensure that healthcare providers continue to receive the support necessary to deliver effective allergen immunotherapy. According to the companies, this approach underscores a shared commitment to improving the management of allergic rhinitis and enhancing quality of life for patients living with respiratory allergies.
Stallergenes Greer expressed its deep gratitude to Shionogi for its 13 years of partnership, during which time the two companies contributed significantly to the establishment of Actair® as a leading immunotherapy treatment in Japan. Shionogi’s contributions have been instrumental in raising awareness of allergen immunotherapy and in building the product’s reputation among healthcare providers and patients alike.
Looking ahead, Stallergenes Greer welcomes CEOLIA as its new promotional partner. CEOLIA Pharma, a company with growing expertise and presence in the allergy and respiratory therapeutic space, is expected to bring new energy and strategic focus to the commercialization of Actair®. Stallergenes Greer emphasized its confidence in CEOLIA’s ability to effectively promote the product and continue the legacy of delivering high standards of care to patients.
The partnership with CEOLIA is also aligned with Stallergenes Greer’s broader mission to expand global access to allergen immunotherapy solutions and ensure that patients in all markets can benefit from innovative and individualized allergy care.
About Actair®
Actair® is a prescription sublingual immunotherapy tablet developed by Stallergenes Greer for the treatment of house dust mite-induced allergic rhinitis. It is designed for daily oral administration and works by gradually exposing the immune system to specific allergens, thereby modifying the allergic response and reducing symptoms over time. Actair® is part of Stallergenes Greer’s portfolio of evidence-based AIT (allergen immunotherapy) treatments and is available in several markets globally.
About Stallergenes Greer
Stallergenes Greer is an international biopharmaceutical company headquartered in Baar, Switzerland, focused on the diagnosis and treatment of respiratory allergies through allergen immunotherapy (AIT). With more than a century of expertise and innovation in allergy care, the company offers a range of subcutaneous and sublingual immunotherapy treatments, diagnostic tools, and allergen extracts. Stallergenes Greer operates in over 40 countries, serving millions of patients worldwide.
Through strategic partnerships, scientific rigor, and a deep commitment to improving patient outcomes, Stallergenes Greer continues to play a pioneering role in allergy care, supporting both patients and healthcare professionals with advanced therapeutic solutions.
As the company now enters a new chapter in Japan with CEOLIA, the transition is expected to not only sustain but further enhance access to Actair® and the broader promise of allergen immunotherapy in one of Asia’s most dynamic healthcare markets.
